✦ LIBER ✦

Ranibizumab in South Korean and Taiwanese patients with age-related macular degeneration: primary outcome of the EXTEND III study

✍ Scribed by Fenq-Lih Lee; Oh-Woong Kwon; Hum Chung; Chi-Chun Lai; Shwu-Jiuan Sheu; Young-Hee Yoon; on behalf of the EXTEND III Study Group

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

EXTEND III: Efficacy and safety of ranib

✍ Oh-Woong Kwon, Fenq Lih Lee, Hum Chung, Chi-Chun Lai, Shwu-Jiuan Sheu, Young-Hee 📂 Article 📅 2012 🏛 Springer-Verlag 🌐 English ⚖ 222 KB

EXTEND-I: safety and efficacy of ranibiz

✍ Yasuo Tano; Masahito Ohji 📂 Article 📅 2010 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 305 KB

Long-term efficacy and safety of ranibiz

✍ Yasuo Tano; Masahito Ohji; on behalf of the EXTEND-I Study Group 📂 Article 📅 2011 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 350 KB

Initial experience with aflibercept in t

✍ Cervera, R.E.; Castro, V.; Montero, J.; Torralba, C.; Gracia, A. 📂 Article 📅 2014 🏛 Elsevier ⚖ 387 KB

PSS10 Cost- Effectiveness of Ranibizumab

✍ Arreola-Ornelas, H.; Rosado-Buzzo, A.; García-Mollinedo, L.; Dorantes-Aguilar, J 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

PSS15 THE COST-EFFECTIVENESS OF RANIBIZU

✍ A Turpcu; JW Hay 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB